Aim: The effects of treatment with hydrochlorothiazide (HCTZ) combined with amiloride were elucidated and compared to HCTZ treatment alone and combined with acemetacin or triamterene in a Japanese adult patient with congenital nephrogenic diabetes insipidus. Methods: The study was divided into seven periods: (1) HCTZ and acemetacin; (2) control period; (3) HCTZ; (4) a second control period; (5) HCTZ and amiloride; (6) a third control period, and (7) HCTZ and triamterene. Fluid intake, urine volume, urinary Na, K, creatinine, and osmolality and serum Na, K, Cl, CO2, and osmolality were measured, and free water clearance and proximal and distal tubular Na reabsorption rates were calculated. Results: Without drug administration, the urine volume was about 8,000 ml/day. The urine volume was reduced to about 6,000 ml/day with HCTZ. A further urine volume reduction to about 5,000 ml/day was obtained with the second drug administration, and the effects were similar among the three regimens. Serum and urinary osmolality and free water clearance were also similar among the three combinations, whereas the urinary potassium excretion was the least, and the serum potassium concentration was the highest with HCTZ plus amiloride. Besides, no alkalosis was observed only with this combination. Conclusion: HCTZ plus amiloride may be superior to HCTZ plus acemetacin and HCTZ plus triamterene in preventing hyperkaliuria, hypokalemia, and metabolic alkalosis.

Keywords:
Nephrogenic diabetes insipidus, Hydrochlorothiazide, Prostaglandin synthetase inhibitor, Amiloride, Triamterene
1.
Bichet DG, Oksche A, Rosenthal W: Congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1997;8:1951–1958.
2.
Bichet DG: Nephrogenic diabetes insipidus. Am J Med 1998;105:431–442.
3.
Birnbaumer M: Vasopressin receptor mutations and nephrogenic diabetes insipidus. Arch Med Res 1999;30:465–474.
4.
Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W: Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992;357:333–335.
5.
Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S: Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361:549–552.
6.
Rosenthal W, Seibold A, Antaramian A, Lonergan M, Arthus MF, Hendy GN, Birnbaumer M, Bichet DG: Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 1992;359:233–235.
7.
Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, van Oost BA: Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994;264:92–95.
8.
Crawford JD, Kennedy GC, Hill LE: Clinical results of treatment of diabetes insipidus with drugs of the chlorothiazide series. N Engl J Med 1960;262:734–742.
9.
Blachar Y, Zadik Z, Shemesh M, Kaplan BS, Levin S: The effect of inhibition of prostaglandin synthesis on free water and osmolar clearances in patients with hereditary nephrogenic diabetes insipidus. Int J Pediatr Nephrol 1980;1:48–52.
10.
Alon U, Chan JC: Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus. Am J Nephrol 1985;5:9–13.
11.
Knoers N, Monnens LA: Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus. J Pediatr 1990;117:499–502.
12.
Uyeki TM, Barry FL, Rosenthal SM, Mathias RS: Successful treatment with hydrochlorothiazide and amiloride in an infant with congenital nephrogenic diabetes insipidus. Pediatr Nephrol 1993;7:554–556.
13.
Kirchlechner V, Koller DY, Seidl R, Waldhauser F: Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. Arch Dis Child 1999;80:548–552.
14.
Demura M, Takeda Y, Yoneda T, Furukawa K, Usukura M, Itoh Y, Mabuchi H: Two novel types of contiguous gene deletion of the AVPR2 and ARHGAP4 genes in unrelated Japanese kindreds with nephrogenic diabetes insipidus. Hum Mutat 2002;19:23–29.
15.
van Lieburg AF, Knoers NV, Monnens LA: Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1999;10:1958–1964.
16.
Schöneberg T, Yun J, Wenkert D, Wess J: Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide. EMBO J 1996;15:1283–1291.
17.
Schöneberg T, Sandig V, Wess J, Gudermann T, Schultz G: Reconstitution of mutant V2 vasopressin receptors by adenovirus-mediated gene transfer: Molecular basis and clinical implication. J Clin Invest 1997;100:1547–1556.
18.
Crawford JD, Kennedy GC: Chlorothiazide in diabetes insipidus. Nature 1959;183:891–892.
19.
Kennedy GC, Crawford JD: A comparison of the effects of adrenalectomy and of chlorothiazide in experimental diabetes insipidus. J Endocrinol 1961;22:77–83.
20.
Skadhauge EI: Investigations into the thiazide-induced antidiuresis in patients with diabetes insipidus. Acta Med Scand 1963;174:739–749.
21.
Magaldi AJ: New insights into the paradoxical effect of thiazides in diabetes insipidus therapy. Nephrol Dial Transplant 2000;15:1903–1905.
22.
Ellison DH, Velazquez H, Wright FS: Thiazide-sensitive sodium chloride cotransport in early distal tubule. Am J Physiol 1987;253:F546–F554.
23.
Chevalier RL, Rogol AD: Tolmetin sodium in the management of nephrogenic diabetes insipidus. J Pediatr 1982;101:787–789.
24.
Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984;310:563–572.
25.
Feuerstein G, Zilberman Y, Hemmendinger R, Lichtenberg D: Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats. Neuropsychobiology 1981;7:67–73.
26.
Batlle DC, Grupp M, Gaviria M: Amelioration of polyuria in lithium treated patients by a specific and novel approach using amiloride. Clin Res 1983;31:424.
27.
Costanzo LS: Localization of diuretic action in microperfused rat distal tubules: Ca and Na transport. Am J Physiol 1985;248:F527–F535.
28.
Sonnenberg H, Honrath U, Wilson DR: Effects of amiloride in the medullary collecting duct of rat kidney. Kidney Int 1987;31:1121–1125.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.